PMID- 19797418
OWN - NLM
STAT- MEDLINE
DCOM- 20100106
LR  - 20221207
IS  - 1465-3621 (Electronic)
IS  - 0368-2811 (Linking)
VI  - 39
IP  - 12
DP  - 2009 Dec
TI  - Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ 
      dendritic cells in patients with advanced pancreatic cancer.
PG  - 797-806
LID - 10.1093/jjco/hyp112 [doi]
AB  - OBJECTIVE: Chemotherapy and immunotherapy often seem to contradict each other. 
      However, recent reports suggested that the anticancer effects in some 
      chemotherapeutic agents were concerned with immune response. This study was 
      designed to evaluate the immunological reaction by gemcitabine for future 
      clinical trial of combination therapy with gemcitabine and cancer vaccines. 
      METHODS: We evaluated several immunological parameters in patients with advanced 
      pancreatic cancer who received a conventional dose of gemcitabine for 2 months. 
      Twenty-eight patients with metastasis or locally advanced tumor, including 18 
      gemcitabine-naive and 10 with a history of preceding gemcitabine treatment, were 
      enrolled in this study. The patients received gemcitabine 1000 mg/m(2) for 3 
      weeks, followed by 1 week of rest. We monitored the kinetics of lymphocytes, 
      natural killer cells, monocytes, dendritic cells (DC), human leukocyte antigen 
      (HLA)-multimer conjugated with CMV or WT1 peptide, and intracellular cytokine 
      production of interferon-gamma and interleukin-4 by flow cytometry. The T cell 
      receptor (TCR) repertoire was also analyzed. RESULTS: The absolute number and 
      percentage of CD14(+) monocytes and CD11c(+) (myeloid) DC increased with 
      gemcitabine treatment (P = 0.033 and P = 0.021). The percentage of CD123(+) 
      (plasmacytoid) DC also increased (P = 0.034), whereas no significant change was 
      observed in other immune parameters, including multimer, intracellular cytokine 
      production and TCR repertoire. CONCLUSIONS: Our finding that gemcitabine 
      treatment induced the proliferation of CD14(+) monocytes and CD11c(+) DC could 
      support combination therapy with gemcitabine and specific immunotherapy such as 
      peptide vaccination against pancreatic cancers.
FAU - Soeda, Atsuko
AU  - Soeda A
AD  - Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
FAU - Morita-Hoshi, Yuriko
AU  - Morita-Hoshi Y
FAU - Makiyama, Hiroaki
AU  - Makiyama H
FAU - Morizane, Chigusa
AU  - Morizane C
FAU - Ueno, Hideki
AU  - Ueno H
FAU - Ikeda, Masafumi
AU  - Ikeda M
FAU - Okusaka, Takuji
AU  - Okusaka T
FAU - Yamagata, Shizuka
AU  - Yamagata S
FAU - Takahashi, Noriko
AU  - Takahashi N
FAU - Hyodo, Ichinosuke
AU  - Hyodo I
FAU - Takaue, Yoichi
AU  - Takaue Y
FAU - Heike, Yuji
AU  - Heike Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091001
PL  - England
TA  - Jpn J Clin Oncol
JT  - Japanese journal of clinical oncology
JID - 0313225
RN  - 0 (CD11c Antigen)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Lipopolysaccharide Receptors)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 207137-56-2 (Interleukin-4)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - CD11c Antigen/immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - *Cancer Vaccines/analysis/immunology
MH  - Combined Modality Therapy
MH  - Dendritic Cells/immunology
MH  - Deoxycytidine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Female
MH  - Humans
MH  - Immunotherapy
MH  - Interferon-gamma/immunology/pharmacology
MH  - Interleukin-4/immunology
MH  - Killer Cells, Natural
MH  - Lipopolysaccharide Receptors/immunology
MH  - Lymphocyte Activation/immunology
MH  - Male
MH  - Middle Aged
MH  - Monocytes/*immunology
MH  - Pancreatic Neoplasms/cerebrospinal fluid/*immunology/microbiology
MH  - Gemcitabine
EDAT- 2009/10/03 06:00
MHDA- 2010/01/07 06:00
CRDT- 2009/10/03 06:00
PHST- 2009/10/03 06:00 [entrez]
PHST- 2009/10/03 06:00 [pubmed]
PHST- 2010/01/07 06:00 [medline]
AID - hyp112 [pii]
AID - 10.1093/jjco/hyp112 [doi]
PST - ppublish
SO  - Jpn J Clin Oncol. 2009 Dec;39(12):797-806. doi: 10.1093/jjco/hyp112. Epub 2009 
      Oct 1.